In a global biotech industry where venture investors carve own familiar strategy, Versant Ventures has always preferred to go its own way. Versant partners often go off the beaten track to find their startups. They’ll go it alone at the launch point sometimes, or in syndicates. And they have fired up a group of discovery lab operations around the world to help seed the ground with their new biotech creations.
Today, Versant’s team also has an extra $700 million to help fund their next wave of startups. That includes a record $600 million for Fund VII, with a special $100 million carve-out fund that will focus exclusively on Canadian biotechs.
That’s considerably more than the $400 million Fund VI that kicked off 17 biotech ventures for Versant, starting close to 2 years ago.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription